Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Trevena announces advancement of oliceridine clinical development in China » 08:16
06/03/20
06/03
08:16
06/03/20
08:16
TRVN

Trevena

$1.37 /

+0.045 (+3.41%)

Trevena announced the…

Trevena announced the Company's partner in China has been approved by the Chinese National Medical Products Administration to initiate clinical trials for IV oliceridine, Trevena's lead investigational asset for the management of moderate-to-severe acute pain. Jiangsu Nhwa holds an exclusive license agreement for the development and commercialization of oliceridine in China. The Company expects to receive future milestone payments, as well as a 10% royalty on net sales of oliceridine in China.

ShowHide Related Items >><<
TRVN Trevena
$1.37 /

+0.045 (+3.41%)

TRVN Trevena
$1.37 /

+0.045 (+3.41%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
TRVN Trevena
$1.37 /

+0.045 (+3.41%)

Tuesday
Hot Stocks
Trevena collaborates with Imperial College London to evaluate TRV027 » 07:11
06/02/20
06/02
07:11
06/02/20
07:11
TRVN

Trevena

$1.32 /

+0.015 (+1.15%)

Trevena announced it has…

Trevena announced it has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome in COVID-19 patients. ARDS is a major complication leading to mortality associated with COVID-19. Imperial College London will be sponsoring and funding this study, with additional support through the British Heart Foundation Centre for Research Excellence Award. In a COVID-19 infection, the SARS-coronavirus-2 binds to and removes the ACE2 protein in the lungs, causing elevated levels of angiotensin II. This drives overactivation of the AT1 receptor, which results in downstream acute lung injury. This often develops into ARDS, which can ultimately lead to mortality. TRV027 potentially counteracts the disproportionate levels of angiotensin II, by competitively binding to and rebalancing AT1 receptor activation. Additionally, its unique mechanism of action preferentially engages the signaling pathway to promote reparative effects on lung tissue. TRV027 is an investigational new drug that has previously been studied in 691 individuals. It has demonstrated efficacy, potency, and selectivity at the AT1 receptor in nonclinical studies and has a well-characterized pharmacokinetic profile. In previous clinical trials, there was a low dropout rate associated with TRV027, and no significant safety issues were reported. In April 2020, the Company filed a provisional patent application with the United States Patent and Trademark Office covering the use of TRV027 to treat ARDS in COVID-19 patients.

ShowHide Related Items >><<
TRVN Trevena
$1.32 /

+0.015 (+1.15%)

TRVN Trevena
$1.32 /

+0.015 (+1.15%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
TRVN Trevena
$1.32 /

+0.015 (+1.15%)

Over a week ago
Conference/Events
Trevena management to meet virtually with JMP Securities » 04:55
05/08/20
05/08
04:55
05/08/20
04:55
TRVN

Trevena

$0.92 /

+0.0227 (+2.53%)

Virtual Meeting with…

Virtual Meeting with management to be held on May 8 hosted by JMP Securities.

ShowHide Related Items >><<
TRVN Trevena
$0.92 /

+0.0227 (+2.53%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Conference/Events
Trevena management to meet virtually with JMP Securities » 07:33
05/07/20
05/07
07:33
05/07/20
07:33
TRVN

Trevena

$0.90 /

+0.0044 (+0.49%)

Virtual Meeting with…

Virtual Meeting with management to be held on May 8 hosted by JMP Securities.

ShowHide Related Items >><<
TRVN Trevena
$0.90 /

+0.0044 (+0.49%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Over a month ago
Hot Stocks
Trevena announces publication of review of oliceridine data » 07:25
04/23/20
04/23
07:25
04/23/20
07:25
TRVN

Trevena

$0.62 /

-0.03 (-4.62%)

Trevena announced the…

Trevena announced the publication of a review of the clinical and nonclinical data for oliceridine in Drugs of Today. The publication is titled "Oliceridine, a G protein-selective ligand at the mu-opioid receptor, for the management of moderate to severe acute pain", with lead author Tong J. Gan, M.D., Department of Anesthesiology at Stony Brook Medicine. Novel, biased mechanism of action; robust efficacy in animal models with less associated constipation, gastrointestinal dysfunction, and respiratory depression. Novel pharmacology with a half-life that allows for adequate drug concentrations to provide efficacy without drug accumulation or development of active metabolites. No dosage adjustments needed when administering oliceridine to patients with renal impairment, mild to moderate hepatic impairment, or the elderly. Rapid analgesia in hard- and soft-tissue surgeries in patients with moderate-to-severe acute pain. Safe and well-tolerated in a large, open-label, "real world" safety study, including in high-risk patients with advanced age, obesity, and diabetes and across a variety of surgical procedures and settings of care.

ShowHide Related Items >><<
TRVN Trevena
$0.62 /

-0.03 (-4.62%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Conference/Events
Trevena management to meet with JMP Securities » 04:55
03/13/20
03/13
04:55
03/13/20
04:55
TRVN

Trevena

$0.65 /

-0.0371 (-5.42%)

Meeting to be held in…

Meeting to be held in Dallas on March 13 hosted by JMP Securities.

ShowHide Related Items >><<
TRVN Trevena
$0.65 /

-0.0371 (-5.42%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Hot Stocks
Trevena expects to report topline data from TRV250 PoC study in 2H20 » 07:59
03/12/20
03/12
07:59
03/12/20
07:59
TRVN

Trevena

$0.69 /

-0.008 (-1.15%)

Initiated TRV250 acute…

Initiated TRV250 acute migraine PoC study. In November 2019, the Company initiated a proof-of-concept (PoC) study evaluating TRV250 for the treatment of acute migraine and associated anxiety. This randomized, double-blind, single-dose, placebo-controlled study will enroll approximately 120 migraine patients in a validated nitroglycerin (NTG) human migraine provocation model. The primary endpoint of the study is reduction of sustained NTG-induced headaches; secondary outcomes include overall safety measures and reduction of symptomatic anxiety. The Company continues to expect reporting topline data in 2H 2020.

ShowHide Related Items >><<
TRVN Trevena
$0.69 /

-0.008 (-1.15%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Hot Stocks
Trevena says PDUFA goal data for oliceridine NDA set for Aug. 7 » 07:59
03/12/20
03/12
07:59
03/12/20
07:59
TRVN

Trevena

$0.69 /

-0.008 (-1.15%)

Resubmitted NDA and…

Resubmitted NDA and received PDUFA goal date of August 7, 2020. In February 2020, the Company resubmitted the NDA for oliceridine to the FDA, after successfully completing all activities requested in the complete response letter, including a multi-dose healthy volunteer QT study, nonclinical work to confirm levels of an inactive metabolite, and drug product validation reports. In March 2020, the Company announced that FDA had acknowledged receipt of the resubmitted NDA. In their acknowledgement letter, FDA stated that the Company's resubmission was a complete, Class 2 response to the Agency's action letter. A PDUFA goal date has been set for August 7, 2020.

ShowHide Related Items >><<
TRVN Trevena
$0.69 /

-0.008 (-1.15%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Hot Stocks
Trevena expects cash, cash equivalents to fund requirements into 1Q21 » 07:58
03/12/20
03/12
07:58
03/12/20
07:58
TRVN

Trevena

$0.69 /

-0.008 (-1.15%)

Cash, cash equivalents,…

Cash, cash equivalents, and marketable securities were $35.8 million at December 31, 2019. The Company believes that its cash and cash equivalents and marketable securities as of December 31, 2019, together with interest thereon, to be sufficient to fund the Company's operating expenses and capital expenditure requirements into the first quarter of 2021.

ShowHide Related Items >><<
TRVN Trevena
$0.69 /

-0.008 (-1.15%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright
Earnings
Trevena reports Q4 EPS (7c), two est. (8c) » 07:57
03/12/20
03/12
07:57
03/12/20
07:57
TRVN

Trevena

$0.69 /

-0.008 (-1.15%)

"In 2019, we…

"In 2019, we delivered on our plan to establish Trevena as a leading innovator in the treatment of CNS disorders. We completed a significant amount of work to thoroughly address the FDA complete response letter for oliceridine, which positioned us to successfully resubmit the NDA earlier this year. Additionally, we advanced our pipeline, initiating two proof-of-concept studies for acute migraine and opioid use disorder, as well as a collaboration with NIH to evaluate TRV045 for epilepsy," said Carrie Bourdow, President and Chief Executive Officer of Trevena. "We enter 2020 with the same focus and commitment, preparing for the expected approval of oliceridine in the second half of the year, as well as advancing our pipeline assets."

ShowHide Related Items >><<
TRVN Trevena
$0.69 /

-0.008 (-1.15%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
05/31/19 H.C. Wainwright
Trevena assumed with a Buy at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.